BLPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BLPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Bellerophon Therapeutics's retained earnings for the quarter that ended in Sep. 2023 was $-256.32 Mil.
Bellerophon Therapeutics's quarterly retained earnings declined from Mar. 2023 ($-249.26 Mil) to Jun. 2023 ($-254.39 Mil) and declined from Jun. 2023 ($-254.39 Mil) to Sep. 2023 ($-256.32 Mil).
Bellerophon Therapeutics's annual retained earnings declined from Dec. 2020 ($-214.49 Mil) to Dec. 2021 ($-232.25 Mil) and declined from Dec. 2021 ($-232.25 Mil) to Dec. 2022 ($-252.08 Mil).
The historical data trend for Bellerophon Therapeutics's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bellerophon Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Retained Earnings | Get a 7-Day Free Trial | -176.50 | -189.76 | -214.49 | -232.25 | -252.08 |
Bellerophon Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Retained Earnings | Get a 7-Day Free Trial | -247.06 | -252.08 | -249.26 | -254.39 | -256.32 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Bellerophon Therapeutics (OTCPK:BLPH) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Puissance Life Science Opportunities Fund Vi | 10 percent owner | 950 THIRD AVENUE, FL 25, NEW YORK NY 10022 |
Naseem Amin | director | 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827 |
Mary Ann Cloyd | director | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Theodore T Wang | director | C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Scott P Bruder | director | C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827 |
Crispin Teufel | director | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Puissance Capital Fund (gp) Llc | 10 percent owner | 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Parag Suresh Shah | officer: VP of Business Operations | C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059 |
Martin Dekker | officer: See Remarks | 53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827 |
Peter Fernandes | officer: See Remarks | PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827 |
Bobae Kim | officer: VP Reg. Affairs & Quality | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Nicholas Laccona | officer: Controller, (PFO & PAO) | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Steven B Klinsky | 10 percent owner | C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019 |
New Mountain Capital, L.l.c. | 10 percent owner | 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019 |
New Mountain Investments Ii, Llc | 10 percent owner | 787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 05-21-2022
By sperokesalga sperokesalga • 03-31-2023
By sperokesalga sperokesalga • 05-15-2023
By GuruFocusNews GuruFocusNews • 05-12-2022
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocusNews GuruFocusNews • 01-10-2022
By Marketwired Marketwired • 05-27-2021
By Don Li2 Don Li2 • 11-15-2021
By PurpleRose PurpleRose • 07-11-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.